1.2K

How to Secure Point-of-Care Testing and Its Reimbursement in 2026

This article explains how to secure point of care testing and its reimbursement within modern UK and EU payer systems. This guide explains how to secure point-of-care testing and its reimbursement across UK and EU health systems in 2026. Securing point-of-care testing (POCT) and its reimbursement in 2026 requires a clear demonstration of clinical value, pathway integration, and economic benefit. Across Europe and the UK, payers now expect POCT to show measurable improvements in triage, diagnosis, prescribing accuracy, and antimicrobial stewardship, not just rapid turnaround time. As multimorbidity rises and care shifts into community and ICS-based models, POCT has become a core component of modern diagnostic pathways rather than an optional add-on.

To secure reimbursement, manufacturers must generate evidence that aligns with HTA expectations, ICS network priorities, and national payers such as NHS England, CNAM (France), G-BA/InEK (Germany), and RedETS (Spain). These bodies increasingly require POCT to demonstrate that it reduces avoidable ED attendances, prevents unnecessary admissions, lowers follow-up activity, and replaces more expensive laboratory-based steps. Strong interoperability with virtual wards, pharmacy-led services, community diagnostics centres, and digital reporting tools is also essential.

By 2026, payers fund POCT only when clinical utility, workflow optimisation, patient-flow benefits, and system-level economic value are proven in real-world settings. Achieving sustainable reimbursement therefore demands a structured strategy that combines diagnostic accuracy, pathway redesign, governance, digital integration, and credible health-economic modelling.

Why Positioning Now Matters More Than Speed

Historically, POCT justified its adoption based on speed. In 2026, speed is merely the baseline attribute. Payers now assess POCT using a broader framework rooted in value-based diagnostics, cost-consequence modelling, and care-pathway substitution.

A reimbursable POCT solution in 2026 must demonstrate, through real-world evidence, its capacity to:

1. Substitute

Replace an existing step in the diagnostic pathway with an equivalent or superior test (e.g., POCT CRP replacing delayed lab-based inflammatory markers for AMR-guided prescribing).

2. Shift

Move testing from hospitals into Integrated Care Systems, community diagnostic centres, primary care networks, pharmacies, or home environments, thereby reducing reliance on acute infrastructures.

3. Avoid

Prevent avoidable ED attendances, hospital admissions, or follow-up visits — metrics that payers explicitly track as part of cost-control and performance management.

4. Optimise

Enable better triage, risk stratification, and antimicrobial stewardship (AMR is a top-tier payer priority across the UK, France, Germany, and Spain).

POCT platforms that secure reimbursement today are those that can demonstrate diagnostic superiority in real-world pathways, not just laboratory validation. Payers increasingly expect:

• prospective observational evidence showing impact on clinical decision-making,
• cost–consequence models quantifying pathway changes (DNAs avoided, conveyances avoided, antibiotic-days reduced),
• budget impact analyses (BIAs) showing population-level implications,
• integration evidence (EHR connectivity, interoperability, audit trails), and
• evidence of workforce feasibility (training, governance, error rates, quality control).

Health systems fund POCT when it is shown to:

• reduce the number of touchpoints in diagnostic pathways,
• lower emergency and acute care utilisation,
• free clinical time,
• improve treatment precision and stewardship, and
• deliver measurable gains in service productivity.

This is the core reimbursement case: POCT improves system efficiency more than it increases test costs, producing a net economic gain that is attractive to payers under financial pressure.

The Core Reimbursement Case for POCT: What Payers Actually Pay For

Payers no longer reimburse POCT because it is faster; they reimburse POCT when it produces measurable, system-level economic benefit. In 2026, the reimbursement case hinges on four quantifiable mechanisms:

Pathway Substitution (Direct Cost Replacement)

POCT must show that it replaces a slower or more expensive laboratory step without compromising accuracy or governance.
Examples payers recognise:

• POCT CRP replacing delayed lab inflammatory markers in primary care.
• POCT renal function in virtual wards replacing ED-based bloods.
• Rapid syndromic testing substituting multi-step microbiology workflows.

Reimbursement logic:
A slower pathway + clinician time + repeat attendance + DNA risk = higher total cost than a single POCT encounter.

Activity Avoidance (ED, Admissions, Repeat Visits)

This is the most powerful argument for ICS, CNAM, G-BA and RedETS.
POCT must demonstrate its ability to reduce:

• unnecessary ED presentations,
• hospital conveyances,
• short-stay admissions,
• follow-up appointments caused by delayed results.

Real-world data is critical:
“X% of suspected infections avoided admission when POCT result was available during first clinical contact.”

Reimbursement logic:
Avoided high-cost activity outweighs the price of devices and cartridges.

Shifting Care to Lower-Cost Settings

POCT is reimbursable when it enables a systemic shift from hospital to:

• community diagnostic centres (CDCs),
• pharmacy-led testing,
• GP networks,
• virtual wards and urgent community response teams.

This aligns directly with 2026 policy priorities:

• NHS England: shift 30–40% of diagnostic activity out of acute hospitals.
• CNAM: expand community-based diagnostics under parcours de soins.
• G-BA/InEK: incentivise ambulatory-sensitive testing to reduce DRG spend.

Reimbursement logic:
Tests done in community settings = lower tariff, lower workforce cost, higher system productivity.

Optimising Clinical Decisions

POCT must support:

• antimicrobial stewardship,
• targeted prescribing,
• early triage,
• risk stratification,
• rapid rule-in/rule-out for high-risk pathways.

This matters because payers now tie reimbursement to:

• AMR reduction indicators,
• “justified antibiotic-day” metrics,
• reduced diagnostic uncertainty in urgent care.

Reimbursement logic:
Better decisions early prevent expensive complications later.

How to Secure POCT Positioning and Reimbursement in 2026: Clinical Value, Pathways, ICS Networks, Evidence, and Economic Arguments That Payers Accept

Point-of-care testing (POCT) has evolved from a peripheral convenience into a core diagnostic architecture for modern health systems. By 2026, ageing populations, rising multi-morbidity, chronic workforce shortages, AMR pressures, and post-pandemic system redesigns have pushed payers to seek diagnostics that deliver faster clinical decisions, earlier intervention, and lower system costs.

However, speed alone does not secure reimbursement. To obtain durable funding, POCT manufacturers must demonstrate clinical utility, pathway relevance, cost–consequence benefit, and seamless integration across digital, laboratory and community care systems. Payers now expect POCT to:

• displace expensive or slow laboratory steps,
• shift testing out of hospitals into community and pharmacy-led hubs,
• avoid unnecessary ED visits, admissions, and repeat appointments,
• optimise antimicrobial stewardship and prescribing, and
• integrate with virtual wards, triage platforms, and national EHRs.

This creates a new reimbursement landscape: POCT must prove system-level value, not just analytical performance.

POCT in 2026: Why Positioning Now Matters More Than Speed

Historically, POCT justified its existence on turnaround time. In 2026, turnaround time is merely the minimum requirement. Payers evaluate POCT using a value-based diagnostic framework focused on four measurable outcomes:

1. Substitute

Replace an existing laboratory or clinical step without compromising accuracy or governance.

2. Shift

Move diagnostics from hospitals to community diagnostic centres, GP networks, pharmacies, mobile units, and home settings — reducing pressure on acute sites.

3. Avoid

Prevent unnecessary ED attendances, short-stay admissions, unwarranted referrals, and follow-up appointments triggered by delayed results.

4. Optimise

Strengthen antimicrobial stewardship, triage accuracy, and early rule-in/rule-out decisions for high-risk conditions.

Payers reimburse POCT when these four effects generate quantifiable health-economic benefit, validated through real-world evidence.

Who Pays for POCT and How Reimbursement Actually Works Across Europe, the UK, and the USA (Scientific, HTA-Aligned, 2026 Edition)

Securing POCT reimbursement in 2026 requires understanding three scientific and economic realities:

1. POCT is funded differently depending on the care setting (primary care vs hospital vs community).
2. Each country has its own reimbursement logic, but all evaluate POCT through a common HTA lens: clinical utility + pathway impact + system cost reduction.
3. Reimbursement is provided only when POCT replaces, shifts, avoids, or optimises care — because these effects produce measurable economic value.

United Kingdom (NHS England, ICS, CDCs)

Who pays

• Primary care & PCNs: Fund POCT when a single consultation can replace multi-step lab pathways (e.g., CRP, UTI POCT).
• Hospitals / Acute Trusts: Pay internally, but business cases must demonstrate ED flow improvement, reduced admissions, or shorter length of stay.
• Community Diagnostic Centres (CDCs): Budget allocated via ICS; POCT is funded if it supports diagnostic shift away from hospitals.
• Private insurers: Reimburse POCT as part of same-day diagnostic bundles.

Scientific HTA logic

NHS requires evidence that POCT:

• improves clinical decision accuracy,
• supports antimicrobial stewardship,
• reduces diagnostic uncertainty and repeat contacts,
• avoids high-cost activity (ED attendance or admission).

Approval

• NICE HealthTech Evaluation (HTE),
• ICS-level adoption based on a cost–consequence model,
• DCB0129/0160 compliance for POCT with digital outputs.

France (CNAM, HAS, ARS)

Who pays

• Primary care: Via NABM/NGAP laboratory tariffs if POCT is accepted as a direct substitute for conventional lab tests.
• Hospitals: GHS (DRG) budgets; POCT reimbursed if it reduces consumables, isolation time, or length of stay.
• Private sector: CNAM tariff or supplementary private fees.

Scientific HTA logic

HAS evaluates whether POCT:

• improves diagnostic certainty at first contact,
• reduces delays in starting treatment (critical for AMR and infections),
• lowers downstream costs by preventing complications.

Approval

HAS → CNEDiMTS → NABM tariff or regional ARS pilot funding.

Germany (G-BA, InEK, SHI Funds)

Who pays

• Primary care: EBM codes reimbursed by Statutory Health Insurance.
• Hospitals: DRG budgets + NUB top-up for innovative POCT.
• Private sector: GOÄ tariff.

Scientific HTA logic

G-BA requires real-world evidence showing POCT:

• changes clinical behaviour (e.g., more targeted antibiotics),
• prevents avoidable admissions,
• reduces resource utilisation in emergency medicine.

Approval

• G-BA benefit assessment → EBM code or NUB request → OPS procedure alignment.

Spain (RedETS + Regions)

Who pays

• Autonomous Communities fund primary care and hospital POCT.
• Private insurers for specialist-led POCT.

Scientific HTA logic

RedETS asks whether POCT allows earlier diagnosis, reduces referral volume, or supports infection control.

Approval

RedETS → regional inclusion in diagnostic catalogues.

Italy (Regional HTA + LEA Tariffs)

Who pays

• Regional health authorities,
• DRG-funded hospitals,
• Private insurers.

Scientific HTA logic

Emphasis on whether POCT supports:

• early stabilisation,
• reduced imaging or blood-panel reliance,
• shorter observation times in EDs.

Approval

Regional HTA → inclusion in LEA or regional tariff.

Netherlands (ZIN)

Who pays

• Nationwide insurers under mandatory basic insurance.
• Hospitals under DBC (diagnosis–treatment combination) budgets.

Scientific HTA logic

ZIN examines:

• real-world evidence of pathway simplification,
• avoidance of unnecessary GP–specialist referrals,
• contribution to AMR national targets.

Approval

ZIN → basic insurance listing → insurer contract pricing.

Belgium (INAMI/RIZIV + KCE)

Who pays

• National insurance for ambulatory POCT,
• DRG-linked forfaits for hospitals,
• Private insurers for supplementary diagnostics.

Scientific HTA logic

KCE weighs whether POCT:

• reduces diagnostic fragmentation,
• offers earlier rule-in/rule-out for infections or chronic disease,
• reduces repeat consultations.

Approval

INAMI nomenclature revision.

Scandinavian Region (Norway, Sweden, Denmark, Finland)

Norway

• Who pays: Municipal primary care & regional hospitals.
• Logic: Early diagnosis + reduced escalation to specialist care.

Sweden

• Who pays: 21 Regions (high autonomy).
• Logic: Strong emphasis on AMR: CRP POCT widely funded because it reduces inappropriate antibiotics.

Denmark

• Who pays: Regions + municipalities.
• Logic: POCT reimbursed when it reduces hospital dependence and supports shared care.

Finland

• Who pays: Municipalities + KELA support.
• Logic: Focus on early detection in sparsely populated regions.

Poland (AOTMiT + NFZ)

Who pays

• National Health Fund (NFZ) using bundled tariffs for primary and hospital care.

Scientific HTA logic

AOTMiT requires evidence of:

• earlier diagnosis,
• fewer complications,
• reduced need for higher-intensity hospital care.

United States (FDA + CMS + Private Insurers)

Who pays

• CMS (Medicare) via CPT and CLFS rates,
• Private insurers through contract schedules,
• Hospitals via DRG or APC billing.

Scientific HTA logic

CMS requires evidence that POCT:

• reduces readmission risk,
• supports early discharge,
• replaces multi-step lab workflows,
• lowers total cost of care in defined episodes.

Approval

FDA clearance → CPT codes → CMS pricing → private payer contracting.

“Does this POCT reduce total system cost by improving clinical decision-making early in the pathway?”

If the answer is yes, reimbursement follows.
If the evidence is weak, POCT remains unfunded or considered a convenience add-on.

The Evidence Package Required for POCT Reimbursement in 2026

Securing reimbursement for point-of-care testing (POCT) in 2026 requires a much more advanced evidence package than ever before. Health systems in the UK, Europe and the United States no longer reimburse diagnostics simply because they are fast or analytically strong. Today’s HTA agencies and payers expect POCT to demonstrate clinical utility, pathway impact, operational value, and measurable economic benefit.

Modern diagnostics are assessed not as laboratory tools, but as value-based interventions that influence antimicrobial stewardship, patient flow, decision accuracy and overall system productivity. This shift means POCT manufacturers must show what the test changes, not merely what the test detects.

Analytical Validity: Still Essential, No Longer Enough

Payers continue to require robust data on sensitivity, specificity, reproducibility and stability. However, analytical validity must now be proven in real-world environments where POCT is actually used.

Evidence should show reliable performance:

• in GP practices and urgent care
• in pharmacies and community diagnostic hubs
• by nurses, paramedics and non-laboratory operators
• across variable environmental conditions

The key question for HTA bodies is no longer:
“Does the test work?”
but rather:
“Does the test work consistently in the hands of real clinicians in decentralised settings?”

Clinical Utility: How POCT Changes Decisions

Clinical utility is now a central requirement for reimbursement. Payers expect POCT to show:

• earlier and more accurate decision-making
• faster rule-in/rule-out for infections
• improved triage in primary care and EDs
• reduced unnecessary antibiotic prescribing
• earlier discharge and fewer repeat visits

Evidence must come from real-world or pragmatic studies, including observational cohorts, decision-impact analyses and pathway audits.

Tests that show strong analytical performance but do not change clinical behaviour rarely secure formal reimbursement.

System Impact: The Core Economic Argument

The most important part of the 2026 evidence package is system impact — how POCT changes healthcare utilisation.

Payers expect quantified evidence showing reductions in:

• emergency department attendances
• avoidable hospital admissions
• length of stay
• unnecessary laboratory panels or imaging
• ambulance conveyances
• repeat GP or urgent care consultations

This is the foundation of reimbursement because it translates POCT into system-level savings.

Countries including the UK (ICS), France (CNAM), Germany (G-BA), the Netherlands (ZIN), Belgium (INAMI), and the USA (CMS) now place system impact at the centre of HTA.

Cost–Consequence & Budget Impact Modelling

To demonstrate economic value, manufacturers must provide models that map the entire diagnostic and treatment pathway.

Cost–consequence analysis (CCA) is now preferred over cost-effectiveness analysis for POCT because it captures multiple downstream effects, such as:

• behaviour change
• avoided escalation
• reduced diagnostic fragmentation
• shorter clinical pathways

In major markets, budget impact analyses (BIAs) are mandatory. These models must show how POCT affects system costs over 1-, 3-, and 5-year scenarios.

Payers want to know:
“Does POCT reduce total cost of care when scaled across real services?”

Implementation Feasibility & Governance

HTA bodies now examine whether POCT can be deployed safely, consistently and at scale.

Required evidence includes:

• training requirements and competency data
• operator error rates
• quality-control mechanisms
• device durability
• integration with EHR and lab information systems
• compliance with ISO 15189:2022 and digital safety frameworks (e.g., DCB0129/0160 in the UK)

Payers will not reimburse POCT if it risks workflow disruption or data fragmentation.

Population-Level Relevance

Reimbursement is strengthened when POCT supports wider population goals, including:

• diagnostics in remote or rural areas
• reducing health inequalities
• improving access for older adults and multi-morbid patients
• supporting pandemic preparedness and climate-related outbreaks

Countries such as Sweden, Finland, Italy, France and the USA value POCT that expands access and strengthens resilience.

Real-World Evidence (RWE): The Decisive Factor

Real-world evidence is now considered mandatory.
Payers no longer accept theoretical modelling alone — they want confirmation that POCT delivers measurable benefits in actual use.

RWE should be drawn from:

• ICS pilots (UK)
• community diagnostic centres
• urgent community response teams
• hospital EDs and AMUs
• pharmacy-led testing
• early adopters across EU regions

This evidence demonstrates that POCT’s benefits are reproducible, scalable and sustainable.

The 2026 Minimum Evidence Package

To be reimbursed, POCT must demonstrate:

• analytical validity in decentralised settings
• clinical utility that improves decision-making
• system impact that reduces costly utilisation
• economic benefit through CCA and BIA
• operational feasibility at scale
• population relevance
• real-world performance

Payers reimburse POCT only when evidence shows that it changes behaviour, changes outcomes and changes budgets.

How to Position POCT for Maximum Reimbursement Success in 2026

Positioning point-of-care testing (POCT) for reimbursement in 2026 requires more than highlighting analytical speed or convenience. Modern health systems evaluate diagnostics through a value-based lens, meaning manufacturers must clearly articulate POCT as a pathway-changing intervention that directly supports payer priorities: reducing avoidable utilisation, improving antimicrobial stewardship, strengthening community care, and increasing system productivity. The strongest positioning strategies communicate how POCT improves clinical decisions, accelerates treatment, lowers healthcare costs and aligns with national digital and health-policy frameworks.

Speak the Payer’s Language: Outcomes, Not Devices

Payers across the UK, France, Germany, the Netherlands, Belgium, Scandinavia, Italy, Poland and the USA now use the same decision logic: they reimburse diagnostics that prevent unnecessary activity and improve clinical efficiency. Therefore, the positioning narrative must focus on:

• reduced ED attendance and avoidable admissions
• improved triage accuracy
• earlier rule-in/rule-out diagnosis
• fewer unnecessary laboratory panels
• shorter lengths of stay
• measurable AMR stewardship gains

POCT should be described not simply as a test, but as a solution to specific system pressures: freeing bed capacity, reducing congestion, enabling safe community management, and supporting same-day decision-making.

This language resonates directly with ICS leadership in the UK, CNAM committees in France, G-BA evaluators in Germany, ZIN in the Netherlands, INAMI/RIZIV in Belgium, and CMS reviewers in the United States.

Position POCT Precisely in the Pathway

Payers do not reimburse vague or generic diagnostic claims.
They reimburse POCT when it is anchored to a clearly defined decision point where it creates measurable value.

Examples include:

• Primary care: differentiating viral vs. bacterial infection to reduce unnecessary antibiotics.
• Emergency departments: earlier identification of high-risk respiratory infections to avoid observation or admission.
• Virtual wards: enabling safe home monitoring with rapid biochemical or inflammatory markers.
• Pharmacy-led diagnostics: providing accessible, same-day testing to reduce GP and ED demand.

Effective positioning requires showing exactly where in the pathway POCT changes clinical behaviour, and exactly how that change reduces downstream cost.

Build a Diagnostic Value Story: Clinical + Operational + Economic

The strongest reimbursement submissions combine three narratives into one coherent value story:

1. Clinical Value

POCT enables faster, more accurate diagnosis and improves early therapeutic decision-making.
Examples: early pneumonia identification, rapid UTI screening, improved infection differentiation.

2. Operational Value

POCT improves workflow by reducing waiting times, minimising handovers, avoiding repeat visits and supporting streamlined care in community settings.

3. Economic Value

POCT reduces system costs through:

• avoided referrals
• fewer ED presentations
• reduced admissions
• shorter lengths of stay
• better antimicrobial stewardship
• decreased demand for central laboratory testing

Payers want evidence that these three layers work together to deliver measurable whole-system benefit.

Tailor the Reimbursement Dossier to Each HTA Market

Each country has a different reimbursement architecture, and POCT must be positioned to fit:

• UK: align with NICE HTE, ICS business case structures, CDC models and digital safety (DCB0129/0160).
• France: match HAS clinical benefit grading, CNEDiMTS requirements and NABM tariff logic.
• Germany: align with G-BA evidence standards, EBM rules and InEK cost structures for NUB.
• Netherlands: reflect ZIN’s emphasis on real-world outcomes and referral reduction.
• Belgium: demonstrate pathway simplification compatible with INAMI nomenclature and KCE expectations.
• Nordics: emphasise AMR stewardship, decentralised access and early diagnosis in remote areas.
• USA: align with CMS logic for CPT codes, DRG/APC structures and value-based care models.

Positioning must speak to the specific payer’s economic incentives, terminology and policy goals, not a generic European narrative.

Demonstrate Digital Integration & System Readiness

Modern payers expect diagnostics to strengthen the broader ecosystem, not sit in isolation.
Therefore, POCT must be positioned as a digitally integrated, quality-assured system asset, with evidence of:

• seamless EHR, LIS and app-based connectivity
• audit trails and data capture for national reporting
• ISO 15189:2022 POCT governance compliance
• automated QC and minimal operator burden
• low training needs and high reproducibility

Diagnostics that cannot integrate with national digital infrastructure rarely receive sustained reimbursement.

Align POCT with National Health Priorities

Positioning must show how POCT supports current national strategies, such as:

• antimicrobial stewardship (AMR)
• reducing avoidable hospital activity
• shifting diagnostics closer to home
• improving access in underserved populations
• supporting virtual ward expansion
• strengthening pandemic and outbreak response

When POCT is framed as an enabler of national health-policy goals, it moves from being “a test” to becoming a strategic system intervention which is exactly what payers reimburse.

Use Real-World Evidence to Prove Scalability

Finally, the most powerful positioning strategy relies on RWE from early adoption sites, because payers trust real-world performance more than theoretical modelling.

Manufacturers should present evidence from:

• community diagnostic centres (UK)
• urgent community response teams
• ED triage pathways
• primary care pilots
• pharmacy-led diagnostic hubs
• virtual ward evaluations
• early adopter regions in France, Germany, the Nordics or the Netherlands

RWE demonstrates that POCT:

• changes behaviour
• reduces costs
• integrates into workflow
• improves patient experience
• works at scale

This converts the submission from a claim into proof.

What Successful Positioning Looks Like

To win reimbursement in 2026, POCT must be positioned as a pathway-level innovation with evidence of:

• faster, safer clinical decisions
• reduced diagnostic uncertainty
• avoided ED visits and admissions
• better antimicrobial stewardship
• greater community-based care capacity
• measurable system savings
• strong digital and governance integration
• alignment with national priorities
• proven real-world performance

Payers buy system transformation, not devices.
The manufacturers who win are those who show — with clarity and evidence — how their POCT reshapes pathways, improves outcomes, and reduces total cost of care across hospitals, primary care, urgent care and community diagnostics.

Strategic Recommendations for Manufacturers: The Practical Roadmap to POCT Reimbursement in 2026

Winning reimbursement for point-of-care testing (POCT) in 2026 requires a structured, proactive strategy that moves far beyond traditional product launches. Manufacturers must combine strong scientific evidence with payer-oriented communication, real-world validation, regulatory alignment and early pathway integration. The companies that succeed are those that approach POCT not as a device, but as a clinical workflow intervention, cost-avoidance mechanism, and system-efficiency tool.

Below is the practical roadmap that manufacturers should follow to secure POCT reimbursement across key markets.

Define the Exact Pathway Problem the POCT Solves

Every reimbursed POCT begins with a tightly defined clinical and operational problem.
Manufacturers should articulate:

• the decision point where POCT creates value
• the current bottleneck or inefficiency in the pathway
• the consequences of delay (admissions, antibiotic misuse, ED congestion, repeat visits)
• the specific costs the system currently absorbs

This clarity anchors the entire reimbursement strategy.
Payers fund diagnostics that solve a measurable problem, not those with generic utility.

Map National and Regional Reimbursement Routes Early

Reimbursement pathways differ across markets:

• UK: ICS business cases, NICE HTE, CDC networks, AHSN pilots
• France: HAS clinical benefit, CNEDiMTS, NABM tariffing
• Germany: G-BA evidence review, EBM codes, InEK NUB, OPS alignment
• Netherlands: ZIN basic insurance eligibility, insurer contracting
• Belgium: INAMI nomenclature and KCE pathway validation
• Nordics: regional budgets, AMR targets, decentralised diagnostics policies
• Italy: regional LEA alignment and tariff inclusion
• Poland: AOTMiT evaluation, NFZ funding bundles
• USA: CMS CPT coding, CLFS rates, DRG/APC structures, private payer contracts

Manufacturers must tailor dossiers per market, not repurpose a single European submission.

Generate Early Real-World Evidence in the Correct Settings

Payers trust real-world evidence (RWE) more than controlled trials.
Manufacturers should initiate early pilots in:

• primary care networks
• urgent care centres
• emergency departments
• community diagnostic centres
• pharmacy-led testing hubs
• virtual wards and remote monitoring pathways

These sites produce data on:

• clinician behaviour change
• reduced antibiotic prescribing
• avoided ED attendance
• improved triage and faster decision times
• reduced unnecessary lab usage
• patient satisfaction and uptake
• workflow stability

RWE is the single strongest predictor of reimbursement success.

Build a Payer-Focused Economic Model

Diagnostics are no longer judged by analytical validity alone.
Payers require economic clarity, including:

• cost–consequence modelling
• budget impact analysis (1-, 3-, 5-year)
• quantification of avoided costs:
  • ED visits
  • hospital admissions
  • unnecessary imaging
  • prolonged length of stay
  • avoidable referrals
  • unnecessary antibiotic prescribing
  • fewer laboratory panels

The model must be payer-specific:

• ICS: flow, capacity, bed pressure
• CNAM: parcours de soins and national budget
• G-BA: evidence of substitution and improved efficiency
• ZIN: reduction in referrals and overtreatment
• CMS: impact on episodes of care and readmissions

Economic modelling is the backbone of reimbursement.

Prioritise Digital Integration & Governance Compliance

POCT is now part of the digital health infrastructure.
Manufacturers should ensure:

• seamless EHR/LIS connectivity
• integration with prescribing and stewardship tools
• automated result transmission
• audit logs
• compliance with ISO 15189:2022
• adherence to digital safety (e.g., DCB0129/0160 in the UK)
• cybersecurity and data-protection readiness

Diagnostics that do not integrate digitally often fail reimbursement review because they create data fragmentation and governance risk.

Engage Local Clinical Champions Early

Reimbursement accelerates when clinicians advocate for POCT.
Manufacturers should identify:

• GP network leads
• ED and AMU consultants
• community diagnostic centre directors
• stewardship leads
• infectious disease specialists
• respiratory and sepsis champions
• pharmacists in advanced practice roles

Clinicians validate that POCT:

• fits real workflows
• improves decision-making
• reduces bottlenecks
• supports AMR stewardship
• reduces inappropriate escalation

These endorsements matter deeply to HTA committees.

Align POCT Messaging with National Health Priorities

The most successful POCT platforms explicitly support national strategies:

• AMR reduction (UK, FR, NL, SE, DK, NO)
• decentralised diagnostics (all European markets)
• virtual wards / hospital at home (UK, Nordics, US)
• ED decongestion (DE, UK, BE)
• equitable access for rural and remote populations (FI, NO, US)
• chronic disease management (Italy, US, UK)
• pandemic preparedness across all regions

When POCT is framed as a policy enabler, reimbursement becomes far more likely.

Prepare a Country-Specific Reimbursement Dossier

Each dossier should include:

• clinical performance evidence
• real-world data demonstrating pathway change
• cost–consequence and BIA models
• workflow and implementation evidence
• digital safety and interoperability documentation
• governance compliance (ISO + national standards)
• population relevance and equity impact
• alignment with national strategies
• pilot data and clinician endorsements

This structure matches payer expectations across ICSs, CNAM, G-BA, ZIN, INAMI, AOTMiT and CMS.

Build a Multi-Setting Commercial Strategy

POCT thrives when positioned across multiple care environments:

• primary care (infection differentiation, chronic disease)
• ED triage (respiratory, cardiac, infection)
• pharmacies (decentralised testing, AMR stewardship)
• ambulatory care (rapid decision-making)
• virtual wards (biomarker monitoring at home)
• community diagnostics (rapid access + triage)

A multi-setting strategy expands utilisation and strengthens the economic case.

Move Fast: Markets Reward Early Entrants

Health systems are restructuring diagnostics now.
Those who establish early pathways, generate early RWE and secure early payer alignment will dominate.

POCT manufacturers that wait for “perfect” evidence risk losing:

• ICS contracts
• placement in community diagnostic centres
• hospital tenders
• insurer partnerships
• national AMR-funded initiatives

The winners in POCT reimbursement are those who act early, pilot early and publish early.

The Roadmap to POCT Reimbursement Success

To win reimbursement in 2026, manufacturers must deliver a coherent strategy built on:

• clear pathway definition
• market-specific reimbursement intelligence
• compelling real-world evidence
• robust economic modelling
• digital and governance compliance
• national policy alignment
• strong clinical advocacy
• multi-setting deployment
• early payer engagement

POCT is no longer bought as a device — it is bought as a solution.
Manufacturers who present POCT as a clinically essential, economically proven and operationally scalable intervention will secure reimbursement across the UK, EU and USA.

---

Country-by-Country Reimbursement Overview for POCT in 2026

POCT reimbursement varies across healthcare systems, but the underlying payer logic is becoming increasingly aligned: diagnostics must demonstrate clear pathway impact, clinical utility, and system-level cost savings. Below is a concise, strategic overview of how POCT is assessed and reimbursed across major European markets, the UK and the United States.

---

United Kingdom (UK)

Reimbursement for POCT in the UK is now driven primarily by Integrated Care Systems (ICSs), supported by national frameworks such as NICE’s HealthTech Evaluation (HTE), the NHS Payment Scheme, and the national AMR programme.
POCT must show:

• reduced ED attendances
• improved triage
• same-day decision-making in primary care
• support for virtual wards and community diagnostic centres

ICSs often require cost–consequence analysis and real-world evidence from pilots or AHSN-supported deployments. Adoption is accelerated when POCT integrates with EHRs, shared care records and digital safety frameworks (DCB0129/0160).

---

France

In France, reimbursement is authorised through CNAM based on clinical assessment by HAS (specifically CEDiMTS). POCT is typically added to the NABM tariff for primary care or funded under GHS/DRG budgets in hospitals.
HAS evaluates:

• clinical added value
• diagnostic relevance
• system impact
• pathway simplification

POCT positioning is strengthened when it aligns with France’s national AMR plan, regional ARS priorities, and “parcours de soins” optimisation.

---

Germany

Germany remains one of the strictest markets for diagnostic reimbursement.
Success requires:

• G-BA approval for EBM inclusion in ambulatory care
• strong clinical and real-world evidence
• clear demonstration of substitution or improved efficiency

Hospitals may adopt POCT via intra-DRG funding, or seek NUB (Neue Untersuchungs- und Behandlungsmethoden) for innovative diagnostics. InEK requires manufacturers to provide detailed cost data aligned with DRG structures. Germany places heavy emphasis on workflow stability, clinical governance, and quantified cost avoidance.

---

Netherlands

The Netherlands reimburses POCT when it is considered essential under the national basic insurance package approved by ZIN (Zorginstituut Nederland). Dutch insurers are particularly focused on:

• reducing unnecessary referrals
• preventing overtreatment
• improving same-day decision-making
• supporting antimicrobial stewardship

ZIN expects real-world evidence, economic modelling and strong demonstration of clinical behaviour change. Pathway simplification is central to the Dutch HTA logic.

---

Belgium

Belgian reimbursement is administered by INAMI/RIZIV, with scientific evaluation from KCE.
POCT must show:

• pathway simplification
• reduced diagnostic duplication
• improved triage and early treatment decisions

Belgium operates tight DRG-linked forfaits in hospitals, meaning diagnostics must demonstrate cost neutrality or cost savings within predefined budgets. Evidence of improved AMR stewardship is increasingly influential.

---

Nordic Countries (Sweden, Norway, Denmark, Finland)

The Nordics share common reimbursement principles:
Diagnostics are funded regionally and must support:

• decentralised care
• AMR reduction
• early diagnosis
• improved access in rural regions
• stronger community-based management

Sweden: POCT CRP and respiratory POCT are widely reimbursed because they reduce antibiotic prescribing and improve triage.

Norway: Municipal budgets and regional authorities adopt POCT when it prevents escalation to specialist care.

Denmark: Focus on early intervention and primary care decision support drives reimbursement.

Finland: Geographic distribution makes POCT valuable for rural populations.

Nordic payers heavily favour RWE, particularly where POCT improves consistency of care.

---

Italy

Italy’s reimbursement landscape is regionally driven under the national LEA (Livelli Essenziali di Assistenza) framework.
Regions such as Lombardy, Emilia-Romagna and Veneto are more likely to adopt POCT when it supports:

• reduced ED overload
• strengthened primary care
• earlier management of chronic conditions
• streamlined infectious disease pathways

Real-world evidence from Italian pilot centres significantly accelerates adoption.

---

Poland

Poland’s National Health Fund (NFZ) and HTA agency (AOTMiT) evaluate POCT based on:

• early diagnosis
• pathway simplification
• reduction of avoidable hospital activity
• improved outcomes in infectious and chronic diseases

Diagnostics are typically funded inside bundled tariffs, making economic neutrality or savings vital. AOTMiT expects clear modelling and evidence aligned with Polish care pathways.

---

United States

U.S. reimbursement is divided between CMS (Medicare/Medicaid) and private insurers.
POCT reimbursement may occur through:

• CPT codes under the Clinical Lab Fee Schedule (CLFS)
• DRG/APC mechanisms in hospitals
• value-based care contracts with private payers

CMS evaluates diagnostics based on their ability to reduce:

• readmissions
• late presentations
• unnecessary imaging or lab use
• high-cost escalation

Integration into population health models and risk-sharing contracts strengthens adoption.
Real-world performance data from IDNs (Integrated Delivery Networks) and ACOs (Accountable Care Organisations) is increasingly essential.

The Future of POCT and the New Payer Logic

By 2026, point-of-care testing (POCT) has shifted from a peripheral diagnostic luxury to a central pillar of modern health system design. Health services across Europe, the UK and the United States now face the same pressures: ageing populations, increasing multi-morbidity, worsening AMR, critical workforce shortages and persistent congestion in hospitals and emergency departments. In this environment, diagnostics are no longer judged on analytical accuracy alone. They are judged on whether they release system pressure, enable earlier intervention, and reduce avoidable spending.

This is the new payer logic diagnostics must be value-generating, not simply “fast.”

POCT platforms that succeed in securing reimbursement will be the ones that demonstrate clear pathway transformation: fewer unnecessary attendances, earlier rule-in/rule-out decisions, reduced reliance on central laboratories, and stronger antimicrobial stewardship. They must also strengthen digital ecosystems through seamless data capture, EHR integration and robust POCT governance aligned with ISO 15189:2022. The future of reimbursement belongs to diagnostics that behave as components of a connected system, not isolated devices.

The shift toward decentralised diagnostics in primary care, pharmacies, community diagnostic centres, virtual wards and remote monitoring pathways will accelerate. Health systems are actively moving testing closer to the patient, reducing the burden on acute hospitals and enabling new models of care that rely on early, actionable information. This transition is already visible in the UK’s ICS-driven diagnostic strategy, France’s regional ARS initiatives, Germany’s increased reliance on rapid testing in emergency care, and Scandinavian investment in rural and remote POCT access.

For manufacturers, the message is clear. Reimbursement is now won through:

• strong real-world evidence in the intended care setting
• well-defined pathway positioning
• compelling economic arguments
• digital and governance readiness
• alignment with national strategies
• and early engagement with clinicians and payers

POCT reimbursement is no longer a regulatory outcome it is a strategic outcome achieved through evidence, integration, and system alignment.

As global pressures continue to reshape healthcare, the value of decentralised, rapid, decision-changing diagnostics will only grow. Payers will continue to reward POCT platforms that reduce avoidable activity, improve prescribing accuracy, and enable safe care outside hospital walls. The companies that thrive will be those that recognise this shift early, invest in real-world evidence, and position their technology not as a test, but as a solution to systemic challenges.

POCT is becoming one of the defining technologies of this decade.
The winners will be those who prove, with clarity and evidence, that their diagnosis truly changes outcomes, changes behaviour, and changes budgets.

References

1. Clinical & Economic Evidence for POCT

1. El-Osta A, Woringer M, Pizzo E, et al. (2017). Does use of point-of-care testing improve cost-effectiveness of the NHS Health Check programme in the primary care setting? A cost-minimisation analysis. BMJ Open, 7:e015494.
   Available at: https://pubmed.ncbi.nlm.nih.gov/28814583/ PubMed
2. Lingervelder D, Koffijberg H, Kusters R, IJzerman M. (2019). Point-of-care testing in primary care: A systematic review on implementation aspects addressed in test evaluations. International Journal of Clinical Practice, 73(10):e13392.
   Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6790572/ PMC
3. El-Osta A, et al. (2021). How to realise the benefits of point-of-care testing in resource-limited settings: Lessons from the literature. International Journal of Health Policy and Management.
   Available at: https://www.ijhpm.com/article_4151_fbc06fb015c32c6cc31f6a3d6118019d.pdf IJHPM
4. Oeschger T, McCloskey D, Kopparthy V, et al. (2019). Point of Care Technologies for Sepsis Diagnosis and Treatment. Annual Review of Biomedical Engineering, 21:315–338.
   Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6392004/ PMC
5. Bradley Z, O’Dochartaigh C, et al. (2023). Point-of-care diagnostics for sepsis using clinical and molecular biomarkers. Biosensors and Bioelectronics.
   Available at: https://www.sciencedirect.com/science/article/pii/S0956566323001239 ScienceDirect
6. Morris E, et al. (2017). Point-of-care lactate testing for sepsis at presentation to primary care. British Journal of General Practice, 67(665):e859–e865.
   Available at: https://bjgp.org/content/67/665/e859.full-text.pdf British Journal of General Practice
7. European Centre for Disease Prevention and Control (ECDC). (2020). A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control.
   Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Assessment-of-point-of-care-testing-devices-for-infectious-disease-surveillance.pdf ECDC
8. Enne VI, et al. (2025). INHALE WP3: rapid ICU-based syndromic PCR versus standard care in hospital-acquired and ventilator-associated pneumonia. Intensive Care Medicine.
   PubMed record: https://pubmed.ncbi.nlm.nih.gov/39961847/ PubMed
9. Wagner AP, et al. (2025). Cost-effectiveness of rapid ICU-based syndromic PCR in hospital-acquired and ventilator-associated pneumonia: economic analysis of INHALE WP3. Critical Care.
   Available at: https://ccforum.biomedcentral.com/articles/10.1186/s13054-025-05428-1 BioMed Central

---

2. Antimicrobial Resistance, Stewardship & Rapid Diagnostics

10. European Centre for Disease Prevention and Control (ECDC) & WHO Europe. (2025). Surveillance of antimicrobial resistance in Europe, 2024 data – Executive Summary.
    Available at: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2024-data ECDC
11. ECDC. Antimicrobial resistance (AMR) – facts, surveillance and guidance.
    Available at: https://www.ecdc.europa.eu/en/antimicrobial-resistance ECDC
12. OECD & ECDC. (2019, updated 2024). Antimicrobial resistance – Tackling the burden in the European Union.
    Available at (report PDF): https://www.oecd.org/content/dam/oecd/en/publications/reports/2019/03/antimicrobial-resistance-tackling-the-burden-in-the-european-union_e3631398/33cbfc1c-en.pdf OECD
13. EU-JAMRAI (Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections). (2025). Antimicrobial Stewardship in Primary Care – rapid diagnostic tests as tools to improve decision making.
    Event page: https://eu-jamrai.eu/event/ams-in-primary-care/ EU-JAMRAI
14. WHO. (2017–ongoing). Core components for infection prevention and control programmes.
    Available at: https://www.who.int/teams/integrated-health-services/infection-prevention-control/core-components World Health Organization

---

3. POCT Governance, Quality & Digital Safety

15. International Organization for Standardization. (2022). ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.
    Overview (including POCT requirements): https://www.iso.org/obp/ui/ (search “ISO 15189:2022”) iso.org
16. UKAS (United Kingdom Accreditation Service). Point of Care Testing (POCT) Accreditation – ISO 15189:2022.
    Available at: https://www.ukas.com/accreditation/standards/poct/ UKAS
17. NHS England. (2024). Point of care testing in community pharmacy – guidance for commissioners and providers.
    Available at: https://www.england.nhs.uk/primary-care/pharmacy/point-of-care-testing/ NHS England
18. NHS England – Digital. (2025). DCB0129: Clinical Risk Management – its Application in the Manufacture of Health IT Systems.
    Available at: https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/dcb0129-clinical-risk-management-its-application-in-the-manufacture-of-health-it-systems NHS England Digital
19. NHS England – Digital. (2024–2025). Clinical risk management standards DCB0129 and DCB0160 – overview and latest activity.
    Available at: https://digital.nhs.uk/services/clinical-safety/clinical-risk-management-standards NHS England Digital+1

---

4. HTA of Diagnostics & Evaluation Methodology

20. NICE (National Institute for Health and Care Excellence). (2022, updated 2025). NICE health technology evaluations: the manual (PMG36).
    Overview: https://www.nice.org.uk/process/pmg36
    Full PDF: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741 NICE+1
21. Di Ruffano LF, et al. (2023). Health technology assessment of diagnostic tests: a state of the art review of methods guidance from international organisations. Health Policy.
    Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7614237/ PMC
22. ECDC. (2020). A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control.
    Available at: https://www.ecdc.europa.eu/sites/default/files/documents/Assessment-of-point-of-care-testing-devices-for-infectious-disease-surveillance.pdf ECDC
23. Kawalec P. (2018). Health technology assessment of medical devices in Poland. Journal of Health Policy, Insurance and Management.
    PDF: https://ejournals.eu/pliki_artykulu_czasopisma/pelny_tekst/1b5bf4b8-f574-4366-872a-29044c73c94d/pobierz Ejournals

---

5. National HTA & Reimbursement Frameworks (Europe)

United Kingdom

24. NHS England. (2024). Community Diagnostic Centres – programme overview and implementation.
    Available at: https://www.england.nhs.uk/long-read/community-diagnostic-centres/ NHS England

France

25. Haute Autorité de Santé (HAS). (2024). National Committee for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) – missions and remit.
    Available at: https://www.has-sante.fr/jcms/c_2036238/en/national-committee-for-the-evaluation-of-medical-devices-and-health-technologies-cnedimts Haute Autorité de Santé
26. Haute Autorité de Santé (HAS). (2022). Comprendre l’évaluation des actes professionnels.
    Available at: https://www.has-sante.fr/jcms/c_408961/en/comprendre-l-evaluation-des-actes-professionnels Haute Autorité de Santé

Germany

27. Gemeinsamer Bundesausschuss (G-BA). General methods for benefit assessment and role of EBM/NUB in reimbursement decisions. (example methods document)
    Example dossier illustrating G-BA methodology:
    https://www.g-ba.de/downloads/92-975-8101/2024_10_31_Modul3E_Meropenem_Vaborbactam.pdf G-BA
28. Innovationsfonds / InEK / G-BA. (2022). GOAL-ASV Ergebnisbericht – including references to EBM and NUB mechanisms.
    Available at: https://innovationsfonds.g-ba.de/downloads/beschluss-dokumente/305/2022-12-16_GOAL-ASV_Ergebnisbericht.pdf innovationsfonds.g-ba.de

Netherlands

29. Zorginstituut Nederland (National Health Care Institute). Advising on and clarifying the contents of the standard health care benefit package.
    Available at: https://english.zorginstituutnederland.nl/about-us/working-methods-and-procedures/advising-on-and-clarifying-the-contents-of-the-standard-health-care-benefit-package english.zorginstituutnederland.nl
30. Zorginstituut Nederland. Disease models for insured package management – use of models in package assessment.
    Available at: https://english.zorginstituutnederland.nl/about-us/programs/disease-models-for-insured-package-management english.zorginstituutnederland.nl

Belgium

31. INAMI/RIZIV. La nomenclature des prestations de santé (NomenSoft) – searchable nomenclature and tariffs.
    Available at: https://www.riziv.fgov.be/fr/nomenclature riziv.fgov.be
32. INAMI/RIZIV. Nomenclature des prestations de santé – diagnostic tests (example PDF).
    Example: https://www.riziv.fgov.be/SiteCollectionDocuments/nomenclatureart24_20190401_20190531_01_portee.pdf riziv.fgov.be

Poland

33. Agency for Health Technology Assessment and Tariff System (AOTMiT). Home – HTA of medical technologies and tariff system.
    Available at: https://www.aotm.gov.pl/en/ aotm.gov.pl
34. AOTMiT. Health technology assessment guidelines for non-drug technologies (including medical devices and diagnostics).
    Available at: https://www.aotm.gov.pl/en/guidelines/ aotm.gov.pl

---

6. United States – Laboratory & Diagnostic Payment

35. Centers for Medicare & Medicaid Services (CMS). (2024). Clinical Laboratory Fee Schedule (CLFS) – overview and payment rules.
    Available at: https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs CMS
36. Electronic Code of Federal Regulations (eCFR). 42 CFR § 414 Subpart G – Payment for Clinical Diagnostic Laboratory Tests (including PAMA-linked methodology).
    Available at: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G eCFR
37. CMS / Medicare Learning Network. (2025). Clinical Laboratory Fee Schedule: 2025 Annual Update (MM13889).
    Example MAC summary: https://med.noridianmedicare.com/web/jeb/article-detail/-/view/10525/clinical-laboratory-fee-schedule-2025-annual-update med.noridianmedicare.com